LYEL vs TCMD
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LYEL exhibits critical financial weakness, highlighted by a Piotroski F-Score of 1/9, indicating severe deterioration in fundamental health. Despite a speculative 1-year price rally of 178.7%, the company suffers from extreme operating losses (-1,024,633% margin) and negative revenue growth (-45.50%). The valuation is disconnected from fundamentals, evidenced by an astronomical Price/Sales ratio, while insider sentiment remains bearish with consistent selling by top executives.
TCMD exhibits a stable financial foundation with a Piotroski F-Score of 4/9 and an exceptionally strong balance sheet characterized by very low leverage (Debt/Equity 0.07). While the company shows robust revenue growth of 21% and high gross margins, the stock is currently trading at a premium to its Intrinsic Value ($24.19) and significantly above its Graham Number ($13.42). The valuation is further strained by an extreme PEG ratio of 17.79, suggesting the price has outpaced fundamental growth. Imminent regulatory risks regarding CMS Prior Authorization (PAR) requirements starting April 2026 and bearish insider activity create significant headwinds.
Compare Another Pair
Related Comparisons
LYEL vs TCMD: Head-to-Head Comparison
This page compares Lyell Immunopharma, Inc. (LYEL) and Tactile Systems Technology, Inc. (TCMD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.